Leukemia patients who received infusions of their own T cells, after the cells had been genetically engineered to fight the patients' cancerous tumors, reacted to the therapy in a positive way, staying in full remission for over two years. The new therapy was developed by a group of scientists from the Perelman School of Medicine at the University of Pennsylvania and the results will be presented at the American Society of Hematology's Annual Meeting and Exposition...
More...
More...